Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LFB Group
The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
The deal is the fourth major acquisition in the remote monitoring market in the last five weeks after Philips acquired BioTelemetry and Capsule and Hillrom bought Bardy Diagnostics.
Philips will pay $635m for the Massachusetts-based developer of a platform that connects medical devices and electronic medical records in hospitals.
- Other Names / Subsidiaries
- GTC Biotherapeutics, Inc.
- LFB Biotechnologies, S.A.S.
- rEVO Biologics